NFE2L2 and familial pancreatic carcinoma: Notably, suppression of the Nrf2 target HO-1 using siRNA has recently been shown to cause a decrease in proliferation, and an increase in sensitivity to gemcitabine, in pancreatic cancer tissue in vitro and in vivo [40].